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Summary The epithelial proliferation of normal human breast tissue xenografts implanted into athymic nude mice is significantly increased
from basal levels by oestradiol (E2), but not progesterone (Pg) treatment at serum concentrations similar to those observed in the luteal phase
of the human menstrual cycle. Type IGF receptor (IGFR-1) mRNA and protein have been shown to be up-regulated by E2 in MCF-7 breast
cancer cells in vitro in which IGF-I and E2 act synergistically to stimulate proliferation. We have investigated the expression ofthe IGFR-I mRNA
in normal human breast xenografts treated with orwithout E2 or Pg alone and in combination. Northern analysis of 20 gg of RNA extracted from
the breast xenograft samples showed no hybridization with 32P-labelled IGFR-I probe, although an 11-kb species of IGFR-I mRNA could be
seen when 20 .g of RNA extracted from either MCF-7 breast cancer cells or human breast carcinomas was examined in this way. In order to
analyse the expression of IGFR-1 mRNA in breast xenografts, a quantitative reverse transcription - polymerase chain reaction (RT-PCR) was
employed in which RNA loading, reverse transcription and PCR efficiencies were internally controlled. The data indicate that the IGFR-I mRNA
is up-regulated by two to threefold compared with untreated levels by 7 and 14 days E2 treatment. In contrast, 7 or 14 days Pg treatment down-
regulates the receptor mRNA to approximately half that of untreated levels, whereas combination E2 and Pg treatment produced a twofold
increase in IGFR-I mRNA levels compared with untreated tissue. The results are consistent with the suggestion that E2 may act to stimulate
proliferation indirectly via a paracrine mechanism involving IGFs in normal as well as malignant human breast epithelial cells.
Keywords: normal breast; type insulin-like growth factor receptor; reverse transcription - polymerase chain reaction; oestrogen;
progesterone
The type I insulin-like growth factor receptor (IGFR-I) is highly
homologous to the insulin receptor having a heterotetrameric
structure consisting oftwo ligand-binding extracellular x-subunits
and two transmembrane 3-subunits containing a cytoplasmic tyro-
sine kinase domain (Ullrich and Schlessinger, 1990). The IGFR-I
binds, in order of affinity, the insulin-like growth factors IGF-I,
IGF-II and insulin to which the IGFs are structurally related
(Cullen et al, 199la). The IGFs are mitogenic for many cell types
(Daughaday and Rotwein, 1989; Humbel, 1990).
In both normal and malignant human breast tissue, IGF-I and
IGF-II mRNA are expressed by stromal fibroblasts, but generally
not by the epithelium (Yee et al, 1989; Paik, 1992), whereas the
expression ofthe IGFR-I is restricted to epithelial cells (Jammes et
al, 1992). In vitro studies of the breast cancer cells have demon-
strated that the IGFs are potent mitogens (Karey and Sirbasku,
1988), and that their growth-stimulatory effects can be blocked,
both in vitro and in vivo, by a specific antibody (oIR-3) to the
IGFR-I (Arteaga et al, 1989; Cullen et al, 1990). This suggests that
growth, at least ofMCF-7 breast cancer cells, is stimulated via the
type I rather than the type II IGF receptor.
IGF-I, IGF-II or insulin in combination with E2 are synergistic
in their effects on the growth of MCF-7 cells in culture (Stewart
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et al, 1990; Thorsen et al, 1992). Significantly, the expression of
the IGFR-I and its mRNA in MCF-7 breast cancer cells is greatly
increased by E2 treatment (Stewart et al, 1990), which may sensi-
tize the cells to the mitogenic effects of the IGFs. The synergism
between E2 and IGF-I in MCF-7 cells can be abrogated by adding
the aIR-3 antibody, which prevents binding ofIGFs to the IGFR-I
(Thorsen et al, 1992). In another breast cancer cell line, T47D,
treatment with progesterone (Pg) was found to decrease the
expression of the IGFR-1, whereas it had no effects on the growth
ofthe cells (Papa et al, 1991).
Little is known about whether synergism between E2 and the
IGFs is important for the growth of the normal human breast.
Studies of the steroid responsiveness of normal human mammary
epithelial cells in culture have indicated mitogenic effects of E2
(Malet et al, 1988) and growth-inhibitory effects of progesterone
(Gompel et al, 1986). However, other studies have found no effect
of E2 upon human mammary epithelial cell proliferation in vitro
(Richards et al, 1988; Gabelman and Emerman, 1992). In contrast,
insulin, epidermal growth factor (EGF) and transforming growth
factor-ax (TGF-ox) have been shown to be potent mitogens for
normal breast epithelial cells in culture (Gabelman and Emerman,
1992; Perusinghe et al, 1992). We have found no reports of syner-
gism between E2 and the IGFs or insulin in normal human
mammary epithelial cells in vitro. However, in vivo studies of rat
mammary gland development indicate that IGF-I can substitute for
growth hormone to elicit mammary development when adminis-
tered together with E2. Furthermore, E2 treatment can sensitize the
rat mammary gland to the local effects of IGF-I on development
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(Ruan et al, 1995). The suggestion that E2 treatment may increase
levels of the IGFR-I in vivo is further supported by data showing
that E2 treatment regulates IGFR-I expression in the rat uterus
(Ghahary and Murphy, 1989).
The above evidence supports the suggestion that E2 may be
acting in the normal breast in a similar manner to that in human
breast cancer cells in vitro where induction of the IGFR-I by E2
may account for the synergistic effects ofE2 and IGF-I on growth.
We have recently published a study which employed an in vivo
model ofnormal human breast tissue implanted into athymic nude
mice to study the effects of human adult serum concentrations of
E2 and Pg on epithelial proliferation and steroid receptor expres-
sion (Laidlaw et al, 1995). This study showed that E2 at serum
levels seen in the human menstrual cycle stimulated proliferation
ofthe normal human mammary lobular epithelium in breast tissue
implanted into nude mice in a dose-dependent manner. Further-
more, administration ofPg alone or in combination with E2 had no
effect. The objectives of the present investigation were to analyse
the expression of the IGFR-I messenger RNA in the normal
human breast xenografts treated with human serum concentrations
ofE2 and/or Pg.
MATERIALS AND METHODS
Normal breast tissue implants
The normal breast tissue was obtained from patients undergoing
surgery for isolated benign lesions, implanted subcutaneously into
female athymic nude mice and treated with ovarian steroids using
slow-release silastic pellets as described previously (Laidlaw et al,
1995). On excision from the nude mice, the normal breast xenograft
tissue was frozen in liquid nitrogen until extraction of RNA. Six
untreated human breast tumour samples were also obtained from
patients at surgery in the course of studies on receptor expression
and stored frozen in liquid nitrogen until used for assay.
MCF-7 breast cancer cell culture
Approximately 106 cells were plated in 2 ml of normal growth
medium in 50-mm diameter wells. Normal growth medium was
Dulbecco's modified Eagle medium (DMEM) (Gibco BRL,
Paisley, UK) containing 10% fetal calf serum (Seralab, Crawley
Down, Sussex, UK), 2 mm glutamine (Gibco BRL), 1 mM pyruvate
(Gibco BRL), 50 units ml-' penicillin (Gibco BRL), 50 ,ug ml-'
streptomycin (Gibco BRL) and 10 ,ug ml-' insulin (Hypurin,
Baxter Healthcare, Manchester, UK). The cells were allowed to
attach for 24 h and then withdrawn from the oestrogen and serum
by culture for 4 days in withdrawal medium consisting of phenol
red-free modified Eagle medium (Gibco BRL) containing 2 mM
glutamine, 1 mm pyruvate, 50 units ml-' penicillin, 50 gg ml-'
streptomycin, 25 ,ug ml-' transferrin and 10 ,ug ml-' Hypurin.
Withdrawn cells were then cultured in either withdrawal medium
alone orwithdrawal medium supplemented with0.1 nM, 1 nm or 10
nM E2 for 5 days. The culture medium was changed on days 2 and
4 oftreatment and the cells harvested on day 5. Each treatment was
carried out in triplicate and RNA was extracted from these cells.
RNA extraction
The cells were lysed by the application of 2 ml TRIzol reagent
(Gibco BRL), a monophasic solution of phenol and guanidine
isothiocyanate, and passaged through a pipette several times.
Isolation of RNA from either frozen normal breast xenograft
or breast tumour tissue was performed using at least 1 ml of
TRIzol reagent per 50 mg of tissue. The frozen tissue was frag-
mented using a scalpel blade, placed in 1 ml of TRIzol reagent in
an autoclaved microtube and homogenized. The RNA was then
isolated according to the manufacturer's instructions and quanti-
fied by spectrophotometry at 260 nm. The RNA was stored as a
precipitate in 0.3 M sodium acetate (pH 5.2), 70% v/v ethanol at
-70°C. Owing to the small size of normal breast xenograft
samples, several from each treatment group were pooled before
the extraction of RNA for use in Northern blot analysis and quan-
titation by RT-PCR.
Northern blot analysis
RNA (20,ug) for Northern analysis was denatured and applied to
1.2% w/v agarose gels containing 2.2 M formaldehyde prepared
and electrophoresed at 4 V cm-'. RNA was transferred to posi-
tively charged nylon membrane by capillary action after partial
hydrolysis of the RNA (Sambrook et al, 1989). Northern
hybridization was performed by a standard technique (Stewart et
al, 1994) using aC-32P-labelled cDNA probes for either human
IGFR-I (nucleotides 2438-2684; Ullrich, 1991) or human 36B4
(nucleotides 604-974; Rich and Steitz, 1987). The membranes
were exposed overnight in a cassette against a storage phosphor
screen followed by the scanning of the screen on the Molecular
Dynamics 425S Phosphorlmager. The image obtained was
analysed using the Molecular Dynamics ImageQuant software.
Oligonucleotide primers
Oligonucleotide primers were designed in order to amplify
specific regions of cDNA sequences using the polymerase chain
reaction (PCR), which could then either be cloned onto plasmid
vectors orused forthe quantification ofsample rmRNA expression.
The cDNA sequence to be amplified was known to span at least
one genomic intron by reference to the gene exon sequences to
avoid amplification of any genomic DNA contaminants. The
primers were manufactured on an Applied Biosystems (ABI,
Warrington, Cheshire, UK) 394 DNA/RNA synthesizer using
standard phosphoramidite chemistry and deprotected by incuba-
tion in ammonia at 60°C for 4 h. The solvent was evaporated by
centrifugation under vacuum, after which the primers were
dissolved in 1 ml ofdouble autoclaved ultrapure water and quanti-
fied by their absorbance at 260 nm. The human 36B4 house-
keeping control gene primers were designed by reference to
the sequence for the human acidic ribosomal phosphoprotein
PO (Rich and Steitz, 1987), since this has been shown to be
identical in cDNA sequence (Laborda, 1991) to the 36B4 cDNA
originally isolated by Masiakowski et al (1982). For the amplifica-
tion of 36B4 cDNA, a forward primer (36B4-Fl) consisting
of nucleotides (nt) 604-621; 5'-ACATGCTCAACATCTCCC-3'
and a reverse primer (36B4-RI) consisting of nt 957-974; 5'-
TTCAACCTTAGCTGGGGC-3' were manufactured. For the
amplification ofhuman IGFR-I cDNA, a forward primer (IGFR-I-
Fl) consisting of nt 2438-2455; 5'-TGTACCGCATCGATATCC-
3' and a reverse primer (IGFR-I-RI) consisting of nt 2667-2684;
5'-ACACATTATCGCTGATCC-3' were manufactured by refer-
ence to the published sequence (Ullrich, 1991).
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Construction of synthetic standard cDNA
Synthetic standard cDNA was constructed by introducing a unique
restriction enzyme site EcoRI into the wild-type cDNA to allow the
separate quantitiation of wild-type and synthetic cDNA after PCR
amplification, digestion and gel electrophoresis. This was facili-
tated by site-specific substitution of up to three nucleotide residues
within the central portion ofthe DNA sequence to be amplified by
PCR. For PCR-directed, site-specific introduction of an EcoRI
restriction site within this amplified sequence, a further two 36B4
and IGFR-I primers were manufactured containing the EcoRI
recognition sequence at their 5' ends. These were: 36B4-F2, nt
791-806, 5'-CGGAATTCCC.ATTCTATCATCAAC-3'; 36B4-R2,
nt 773-786, 5'-CGGAATTCTGATGCAACAGTT-3'; IGFR-
I-R2, nt 2544-2557, 5'-CGGAATTCATTCCTGGGCCAG-3'; and
IGFR-I-R2, nt 2527-2540, 5'-CGGAATTCTGCTCCTTCTGC-3'.
The wild-type 370-bp (nt 604-974) 36B4 and 246-bp (nt
2438-2684) IGFR-I cDNA sequences were amplified by PCR
using 36B4-Fl and 36B4-R1 primers, and IGFR-I-FI and IGFR-I-
RI primers respectively. The amplified cDNA was cloned onto
pCRII using the TA Cloning System (Invitrogen, San Diego, CA,
USA), and the sequence of these wild-type cDNA clones as
confirmed by dideoxy chain termination sequencing (Sanger et al,
1977). The EcoRI restriction sites were then introduced into these
cDNA sequences by their PCR amplification using the following
pairs ofprimers in separate tubes: 36B4-F1 and 36B4-R2; 36B4-F2
and 36B4-R1; IGFR-I-Fl and IGFR-I-R2; and IGFR-I-F2 and
IGFR-I-RI. This yielded two cDNA products for each cDNA
species, each cDNA fragment containing an EcoRI site at one end.
These sites were then digested with the EcoRI restriction endonu-
clease (Promega, Madison, WI, USA), and the two PCR-generated
fragments corresponding to either 36B4 or IGFR-I cDNA were
mixed in a 1:1 ratio and ligated using T4 ligase (Promega). The
36B4 and IGFR-I cDNA sequences containing the unique EcoRI
restriction site were amplified from the ligation reaction using the
5' and 3' flanking primers (36B4-FI and 36B4-R1, IGFR-I-FI and
IGFR-I-RI respectively). These synthetic standard 36B4 and
IGFR-I cDNAs containing the EcoRI restriction site were then
cloned onto pCRII using the TA Cloning System (Invitrogen).
Sequencing by the dideoxy chain termination method (Sanger et al,
1977) confirmed that the cDNA was identical to the wild-type
cDNA except for the EcoRI site generated by three nucleotide
substitutions in the cDNA.
The plasmid clones containing the synthetic standard cDNAs
were linearized with Hindlll, gel purified, followed by phenol-
chloroform extraction and quantified by spectrophotometric
absorbance at 260 nm. The absolute number of cDNA templates
was calculated using the molecular weight of the plasmid and the
cloned 36B4 or IGFR-I cDNA, and Avogadro's number. A stock
solution containing 1.0 x 109 molecules gl-l of each synthetic stan-
dard cDNA was made by dilution and stored at -70°C. This stock
solution was used to make all further dilutions forquantitative PCR.
Reverse transcription
The total RNA samples isolated from MCF-7 breast cancer cells
and normal human breast xenografts were reverse transcribed into
cDNA by incubation of I ,ug ofheat-denatured RNA for 30 min at
42°C in a 20-,ul reaction volume. The reaction contained 250 ng of
random hexamer primers (Promega), 1 mM dNTPs (Promega), 2 PI
ofMoloney mouse leukaemia virus (MMLV) reverse transcriptase
(Promega) and 1 x reverse transcriptase buffer (Promega). The
reaction was terminated by incubation at 95°C for 5 min. The
cDNA was stored at-70°C.
Polymerase chain reaction (PCR)
The cDNA obtained by the reverse transcription was amplified
by PCR using forward and reverse primers specific to the
sequence. Each amplification reaction (100 pA) contained cDNA,
200 ng of each primer and 200 gM dNTPs (Promega) in Taq DNA
polymerase buffer (Promega) containing 1.5 mm magnesium chlo-
ride. The reaction mix was overlaid with 50 ,il of sterile liquid
paraffin and denatured at 94°C for 5 min on a Hybaid (Teddington,
Middlesex, UK) 'Omnigene' thermal cycler. The polymerization
reaction was hot started to increase the specificity ofthe amplifica-
tion by the addition of 2 units of Taq DNA polymerase (Promega)
at the annealing temperature. The thermal cycler was programmed
to perform cycles ofprimer extension for I min at 72°C, denatura-
tion at 94°C for 30s and annealing at the lowest T,1, of the specific
forward and reverse primers for 30s with the final cycle having a
10-min primer extension time. Where PCR products were to be
labelled with ox-32P-dCTP, 2.5 tCi were added to each reaction.
For each PCR amplification of cDNA, extraneous DNA contami-
nation of the reagents was controlled by the inclusion in each
experiment of a tube containing an equivalent dilution of a reverse
transcription reaction, containing no RNA, in place of the cDNA
sample, along with the same PCR reagents (minus cDNA control).
The absence of amplified DNA in this -cDNA control confirmed
that the reagents and their handling introduced no DNA contami-
nation into the PCR tube. A second control tube for each cDNA
sample contained the corresponding RNA sample that had not
been reverse transcribed, along with the same PCR reagents
(minus reverse transcriptase control; -RT). The absence of ampli-
fied DNA in this -RT control confirmed that the RNA extract was
not contaminated with genomic or extraneous DNA.
Quantitative PCR
A similar method for assaying mRNA species has been described
previously (Backer-Andre and Hahlbrock, 1989) and employed
synthetic standard RNA molecules at a range of concentrations
alongside RNA extracted from tissue samples in the reverse tran-
scription reaction followed by PCR amplification. In the present
study, this has been modified by the use of synthetic standard
cDNA molecules. The differences between samples in the quantity
of RNA reverse transcribed into cDNA were internally controlled
for by normalization against the expression of the house-keeping
gene, 36B4. This modification of the previous method therefore
controls for differences in the amounts of sample RNA and cDNA
put into the assay, as long as the quantity of cDNA in the sample
lies within the range of standard cDNA concentrations assessed.
Approximately I ,tg of total cellular RNA from each sample to be
analysed was reverse transcribed into cDNA. Equal quantities of
sample cDNA, equivalent to 10 ng of reverse-transcribed total
RNA, were amplified for 40 cycles of PCR, as described above,
alongside a range of known quantities of the standard cDNA
(10-107 molecules). For each quantity of the standard cDNA,
the reaction mix contained either 36B4-FI and 36B4-RI primers
or IGFR-I-Fl and IGFR-I-RI primers and [oc-32P]-dCTP in order
to label the DNA product. For each cDNA sample, a master mix
of PCR reagents was prepared to ensure homogeneity of the
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constitutents between tubes, and appropriate minus cDNA and
minus reverse transcriptase control tubes (as described above)
were included. One caveat when using synthetic internal control
cDNA containing the Eco RI restriction site is that the ratio of
sample to standard may be affected by the formation of
heterodimers between sample DNA and standard DNA strands.
This was avoided by subjecting 1% of the PCR-amplified DNA
product obtained after 40 cycles to one further cycle of PCR with
fresh buffer and reagents. At this point, the reaction is once again
in the exponential phase in which essentially every DNA molecule
is amplified, thus forming only homodimeric DNA species
(Backer-Andre and Hahlbrock, 1989). The reaction product was
then digested with EcoRI, separated by polyacrylamide gel elec-
trophoresis and phosphorimaged in order to quantify the relative
amounts of amplified sample and standard cDNA. Polyacrylamide
gels were prepared using 6% Long Ranger (AT Biochem,
Malvern, PA, USA) gel solution. For each RNA sample, duplicate
PCR amplifications were performed against a range of synthetic
standard control cDNA concentrations from 1000 l-l to 1 x 107
1-'. The ratio of sample-standard bands from each duplicate PCR
amplification was calculated and the mean values plotted against
the number of standard cDNA molecules in each reaction, through
which a curve was drawn. The number of cDNA molecules in
the sample is then equal to the point on the curve at which the ratio
of sample-standard is one.
RESULTS
Northern blot analysis does not detect type I IGF
receptor mRNA in total RNA extracted from normal
human breast xenografts
Northern blot analysis confirmed that E, at doses of 0.1, 1 and 10 n
M up-regulated the IGFR-I mRNA in MCF-7 breast cancer cells by
two to threefold, and that it was expressed in breast tumour
samples (data not shown). However, IGFR-I mRNA could not be
detected in the normal breast xenografts by this method. This
confirmed the findings of previous studies, which have indicated
that the level of IGFR-I mRNA in normal breast tissue was either
undetectable or lower than that in breast tumour tissue (Pekonen et
al, 1988; Peyrat et al, 1990).
Manufacture of standard cDNA by PCR-directed site-
specific mutagenesis for use in quantitative RT-PCR
Since Northern blot analysis was not sufficiently sensitive to
detect the IGFR-I mRNA in total RNA extracted from normal
breast tissue xenografts, a quantitative RT-PCR strategy needed to
be developed.
Standard cDNAs containing a single EcoRI restriction enzyme
site not present in the natural cDNA sequence were manufactured
for the regions of the human IGFR-I and 36B4 mRNAs, which
would be amplified by the primers IGFR-I-FI and IGFR-I-Rl, and
36B4-Fl and 36B4-R1 respectively (see Materials and methods).
A site approximately midway through each sequence was chosen,
where an EcoRI recognition sequence could be created by substi-
tuting three nucleotide bases using a form of PCR site-directed
mutagenesis, as described in the Materials and methods.
The PCR-amplified IGFR-I and 36B4 standard sequences were
cloned onto a plasmid vector as described, which was cultured,
purified, linearized by a single restriction enzyme cut within the
plasmid polylinker, repurified and quantified by spectropho-
tometry at 260 nm. A stock solution containing 109 molecules tl&'
of both cDNA standards was then made. A range of known
amounts of standard cDNA as prepared by diluting this stock for
co-amplification alongside the endogenous cDNA that was reverse
transcribed from cellular mRNA.
Validation of the quantitative RT-PCR method for
measuring IGFR-1 gene expression using total RNA
extracted from MCF-7 breast cancer cells
Approximately 1 ,ug ofthe total cellular RNA extracted from each
sample to be analysed was reverse transcribed into cDNA. Equal
quantities of the sample cDNA were then PCR amplified along-
side a range of known quantities of the standard cDNA in a reac-
tion mix containing [32P] dCTP in order to label the DNA product.
The reaction product was then digested with EcoRI, separated by
PAGE and phosphorimaged in order to quantify the relative
amounts of amplified sample and standard cDNA. The ratio ofthe
sample-standard bands from each PCR amplification was calcu-
lated and plotted against the number of standard cDNA molecules
added to each reaction. The number of cDNA molecules in the
sample was presumed then to be equal to the point on the curve at
which the sample-standard ratio was one. Since assessing the
point at which the reaction was exponential for each sample would
have been a lengthy process, this was avoided by subjecting 1% of
the PCR-amplified DNA product obtained after 40 cycles to one
further cycle of PCR with fresh buffer and reagents. At this point,
the reaction was once again in the exponential phase in which
essentially every DNA molecule was amplified ensuring the
formation ofhomodimeric DNA species only.
A preliminary experiment was conducted in order to examine
this phenomenon. MCF-7 IGFR-I and 36B4 cDNAs were sepa-
rately amplified for 40 cycles in the presence of a range of stan-
dard cDNA concentrations. A sample of 1% of the DNA product
was then subjected to a further cycle of PCR with fresh buffer and
reagents and the product of this reaction was then digested with
EcoRI. An equal proportion of the first PCR product with no extra
cycle of amplification was also digested with EcoRI. This showed
that the effect of one extra cycle of PCR did not greatly alter the
estimation ofthe number ofIGFR-I cDNA molecules, but reduced
the estimation of the number of 36B4 cDNA molecules by more
than half. This implied that the plateau phase of PCR for 36B4
cDNA amplification had been reached after 40 cycles, but that
IGFR-I cDNA amplification had remained in the exponential
phase. In all subsequent experiments, the dilution step followed by
an extra cycle of PCR amplification was performed, so that the
effects of the plateau phase on the formation of heterodimeric
DNA species could be excluded.
In the final step of validation, the cDNA reverse transcribed
from MCF-7 RNA was studied. MCF-7 sample cDNA, prepared
from RNA extracted after either no treatment or treatment with 10
nM E2, was separately amplified alongside a range of standard
cDNA concentrations following the protocol for avoiding the
formation of heterodimeric species. The phosphorimages obtained
after digestion with EcoRI and separation by 6% polyacrylamide
electrophoresis are shown in Figure 1A and B respectively. The
ratios of sample-standard DNA product bands quantified by
volume integration were calculated and plotted against the number
of standard cDNA molecules (Figure 2A and B) and the point on
the curve at which the ratio of IGFR-I or 36B4 equalled one was
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Figure 1 The phosphorimages show the relative amounts of endogenous
cellular cDNA amplified by PCR in the presence of increasing concentrations
of standard cDNA. The samples analysed were cDNA reverse transcribed
from (A) untreated MCF-7 breast cancer cell RNA and (B) 10 nM E2-treated
MCF-7 RNA. The amplified cellular and standard DNA bands were separated
by PAGE on a 6% gel and the bands imaged after overnight exposure to
storage phosphor screens. The resulting bands were quantified by volume
integration of the phosphorimage
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Figure 3 Summary of the data obtained by quantitative RT-PCR using a
standard cDNA to estimate the IGFR-1 mRNA expression in both MCF-7 and
normal breast samples. For MCF-7 cells, each bar shows the amount of
IGFR-1 mRNA expressed as a percentage of that found for untreated cells.
All RNA samples used were pooled from several experiments and analysed
in duplicate. The column representing the results from xenografts treated for
7 days with E2 has an error bar, which is the result of analysis of three
separate pools of xenograft samples from which RNA was extracted
read from the x-axis. As a further control for RNA loading and the
efficiency ofthe RT reaction, the amount ofIGFR-I cDNA initially
present in the sample was calculated as a percentage ofthe amount
of36B4. The untreated sample contained IGFR-I cDNA at 5.6% of
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Figure 2 The ratios of cellular to standard 36B4 or IGFR-1 DNA obtained
from the phosphorimage in Figure 1 were plotted as the mean of duplicates
± standard error (s.e.) against the initial standard 36B4 or IGFR-1 cDNA
concentration. At the point on the curve at which the ratio equalled 1:1, the
sample IGFR-1 or 36B4 concentration was read. The level of expression of
IGFR-1 mRNA in the initial sample was then calculated as a percentage of
the expression of the housekeeping gene, 36B4. A shows the results
obtained using RNA extracted and reverse transcribed from untreated
MCF-7 cells, whereas B shows the results from cells treated with 10 nM E2
the levels of 36B4 cDNA, whereas the 10 nM E2-treated sample
contained IGFR-I cDNA at 15.6% ofthe levels of36B4. This indi-
cated a 280% increase in IGFR-I mRNA levels (Figure 3) and was
in agreement with the increase detected by Northern analysis.
Measurement of the effects of E2 and Pg treatment on
IGFR-1 mRNA expression in normal human breast
tissue xenografts by quantitative RT-PCR
The pooled xenograft sample cDNAs were analysed according to
the RT-PCR methodology developed and validated as above. The
xenograft samples were either untreated, treated with a 4 mg Pg
pellet for 7 or 14 days, treated with a 2 mg E2 pellet for 7 or 14
days, or treated with a combination of 2 mg of E2 for 14 days
combined with 4 mg of Pg for the final 7 days. The data obtained
using this quantitative RT-PCR method indicated that 7 and 14
days' Pg treatment decreased IGFR-I mRNA levels to 30% and
60%, respectively, of the levels found in untreated xenografts
(Figure 3). However, increases in IGFR-I gene expression of250%
(mean of analysis of three different pools of xenograft RNA
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samples) and 230% were observed after 7 and 14 days' treatment
of xenograft with 2 mg of E2 compared with no treatment (Figure
3). In those treated with the combination of E2 and Pg, an increase
in IGFR-I gene expression of 200% compared with no treatment
was observed (Figure 3).
DISCUSSION
In the study described above, we have shown that the normal
breast expresses levels of the IGFR-I mRNA that are undetectable
by Northern blot analysis, whereas the IGFR-I mRNA expression
in breast cancer cells and tissue was easily detected. We have,
therefore, developed a method of RT-PCR in order to quantitate
changes in IGFR-I mRNA levels occurring when normal breast
tissues implanted into nude mice were treated with human luteal
phase serum concentrations of E2 and/or Pg. We have previously
published evidence that proliferation is controlled by E, in this
model (Laidlaw et al, 1995), and we wished to determine whether
changes in growth factor receptor expression could partly account
for this mitogenic effect ofE2.
The method of quantitative RT-PCR that we have developed
internally controlled for the different efficiencies of reverse tran-
scription between extracted RNA samples, since the IGFR-I cDNA
levels were normalized against levels of the constitutively
expressed house-keeping gene, 36B4, cDNA. Expression of the
36B4 house-keeping gene has been widely used for normalization
of RNA levels as assessed by RNAase protection assay both in
breast cancer and in normal cells in vitro (Bronzert et al, 1987;
Cullen et al, 1991b), and in breast cancer xenografts in vivo
(Brunner etal, 1993), since it was first isolated as a gene the expres-
sion of which was unaffected by E2 treatment of MCF-7 breast
cancer cells (Masiakowski et al, 1982). The product of the 36B4
gene has subsequently been shown to be identical to a ribosomal
protein whose mRNA is constitutively expressed (Laborda, 1991;
Krowczynska et al, 1989). The ratio between IGFR-I and 36B4
mRNA in the cellular sample should be equivalent to that seen after
reverse transcription into cDNA, assuming that theefficiency ofthe
reverse transcription of the IGFR-I mRNA and the 36B4 mRNA
into theirrespective cDNAs was equivalent. Since the primers used
in the reverse transcription were random hexamers, there seems to
be no reason why this should not have been the case. The present
method differs from theoriginal methods described forthequantifi-
cation of cellular mRNAs (Backer-Andre and Hahlbrock, 1989;
Wang et al, 1989) in that the present study used known quantities of
a standard cDNA, whereas these investigators used known quanti-
ties of a standard cRNA. Our method is similar to that described
by Gilliland et al (1990) and has the advantage that the prepared
standard cDNAs are stable over many months of storage with
little degradation, whereas RNA is easily degraded (Sambrook et
al, 1989). In contrast to the method of Gilliland et al (1990),
however, the quantification of an endogenous cellular control gene
mRNA, such as the house-keeping gene, 36B4, has been carried out
in order to control internally for the amount of cDNA reverse tran-
scribed from the cellular mRNA. This has advantages over the
previously described studies, which require equivalent amounts of
each sample mRNA to be reverse transcribed in order to compare
the levels of a particular mRNA between samples. The present
assay method controls internally for differences in the amounts of
sample RNA and cDNA, and suggests that it could be applied to
RNA samples that are too small to be quantified by conventional
means, for example, RNA extracted from single frozen sections,
microdissected areas of sections or fine needle aspirates of cells
from the normal breast in vivo.
The application of this method to the cDNA samples obtained
by reverse transcription allowed quantitative assessment of the
changes in IGFR-I mRNA expression in MCF-7 and normal breast
xenograft samples treated with ovarian steroid hormones. In
untreated MCF-7 cells, IGFR-1 mRNA was calculated to be at
5.4% ofthe levels of36B4 mRNA, whereas 5 days' treatment with
10 mm E2 increased the level of IGFR-I to 15% of the levels of
36B4. This threefold increase is identical to the increase observed
in IGFR-I levels by Northern blot analysis. A similar increase in
IGFR-I mRNA expression was seen in the samples of normal
tissue treated in vivo with E,. In contrast, Pg treatment reduced
IGFR-I mRNA levels to 30% and 60% of those in xenografts
taken from untreated mice.
As far as we know, this is the first time that up-regulation ofthe
IGFR-I mRNA by E2 and its down-regulation by Pg in normal
breast tissue has been reported. These findings are consistent with
the observed up-regulation of IGFR-I mRNA observed in MCF-7
breast cancer cells treated with E2 in our study and others (Stewart
et al, 1990; Thorsen et al, 1992), and with the observed down-
regulation ofIGFR-I mRNA observed in T47D breast cancer cells
treated with Pg (Papa et al, 1991). These previous studies ofE2 and
Pg effects on IGFR-I showed that the changes in mRNA levels
were reflected by equivalent changes in levels of the cell
membrane receptor (Stewart et al, 1990; Papa et al, 1991). In the
present study, we have not quantified the changes in cell surface
IGFR-I concentrations. However, using ['25I]IGF-I hisoautoradio-
graphy (Jammes et al, 1992), we confirmed that the IGFR-I is
expressed solely on the epithelial component of xenografted
normal human breast tissue (data not shown). Although the IGFR-
I mRNA levels measured by RT-PCR could be affected by
changes in the ratio ofepithelial to stromal cells in the xenografts,
no change to this ratio in response to ovarian steroid administra-
tion was observed as assessed by histological examination of the
xenografts (Laidlaw et al, 1995).
Since the IGFR-I is the mediator of the mitogenic response to
IGFs (Cullen et al, 1990), its up-regulation by E2 is likely to have
biological significance in the normal breast. The IGFs are secreted
by adjacent normal human breast stromal fibroblasts (Yee et al,
1989; Cullen et al, 1991b; Paik, 1992). This secretion may itselfbe
increased by E2 through the paracrine actions of E2-stimulated
epithelial secretion of platelet-derived growth factor (PDGF),
which stimulates breast fibroblasts to secrete IGFs (Bronzert et al,
1987), or through the synergistic action of E2 with growth
hormone on breast fibroblast IGF secretion, as reported in the rat
mammary gland (Ruan et al, 1995). IGFs are also available to the
normal breast epithelium via an endocrine pathway, since IGF-I is
secreted by the liver throughout adult life, although at higher
serum concentrations in younger than older women as its secretion
is related to growth hormone levels (Clemmons and Van Wyk,
1984). Thus, the sensitivity of the normal breast tissue to mito-
genic stimulation by E, in a particular woman may be partly
dependent on her circulating levels of IGF-I, and possibly IGF-II,
as well as the up-regulation ofthe IGFR-I within the epithelium of
the mammary gland.
In conclusion, the present study has indicated that the type I IGF
receptor mRNA is expressed in normal breast tissue, but at a lower
level than in breast cancer cells in vitro, or in breast tumour tissue.
The mRNA expression ofthe IGFR-I gene could not be detected in
normal breast xenografts by Northern blot analysis, although it was
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easily detected in breast cancer cells and breast tumour samples. A
quantitative RT-PCR method has been developed to assess the
effects of steroid hormone treatment on xenografts of normal
breast tissue. This has produced data that indicate up-regulation of
the IGF receptor mRNA by human luteal phase serum concentra-
tions ofE., and down-regulation of the receptor mRNA by human
luteal phase serum concentrations ofPg, but only in the absence of
El. In the context ofknowledge about the actions ofIGFs on breast
cancer cells in vitro, an up-regulation ofthe type I IGF receptor by
El may lead to synergistic effects ofE2 and IGFs on normal breast
epithelial cell growth in vivo. This combined action ofE2 and IGFs
on cell growth suggests that exposure to both these mitogens could
adversely affect the risk ofdeveloping breast cancer.
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